Loading…
Eton Pharmaceuticals, Inc. is projected to rise to $48.20 by 2027, a +32% move from its current price of $36.61. ETON is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $35.80 | $36.62 | $37.45 | +0.02% |
| Jul 14 | $35.47 | $36.62 | $37.81 | +0.03% |
| Jul 15 | $35.23 | $36.63 | $38.09 | +0.05% |
| Jul 16 | $35.02 | $36.64 | $38.33 | +0.07% |
| Jul 17 | $34.84 | $36.64 | $38.54 | +0.09% |
| Jul 18 | $34.68 | $36.65 | $38.73 | +0.10% |
| Jul 19 | $34.53 | $36.65 | $38.91 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $34.53 | $36.65 | $38.91 | +0.12% |
| Week 2 | $33.73 | $36.70 | $39.93 | +0.24% |
| Week 3 | $33.14 | $36.74 | $40.75 | +0.37% |
| Week 4 | $32.65 | $36.79 | $41.45 | +0.49% |
| Week 5 | $32.23 | $36.83 | $42.09 | +0.61% |
| Week 6 | $31.86 | $36.88 | $42.68 | +0.73% |
| Week 7 | $31.53 | $36.92 | $43.24 | +0.86% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals, Inc. trades at $37.50 per share and has a market cap of $1.03B.
The asset is ranked 2483. It sits in the Healthcare sector with a current price near the high end of its recent activity as reflected in the 30-day range and forecast trajectory.
Forecasts indicate a rising price path through the coming years, with a 2026 average of $37.50 and a long-term trajectory toward a 2050 average of $652.80 and a max of $1,125.67. The upside is underscored by max values such as $132.40 (2030), $451.97 (2040) and $1,125.67 (2050) and a bullish multi-year sentiment showing progressively higher averages and robust ROI milestones.
A major floor 54.4% below — a decisive break under it would weaken the trend.
The nearest floor, 25.2% below — buyers have tended to step in here.
The nearest ceiling, 3.9% above — a clean break opens room to run.
A major ceiling 21.9% above — clearing it would confirm fresh momentum.
Key ETON support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ETON market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $37.17 | Sell | $36.88 | Sell |
| MA 10 | $36.86 | Sell | $36.41 | Buy |
| MA 20 | $34.85 | Buy | $35.09 | Buy |
| MA 50 | $32.04 | Buy | $31.95 | Buy |
| MA 100 | $26.79 | Buy | $28.13 | Buy |
| MA 200 | $21.98 | Buy | $23.85 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.68 | Neutral |
| Stoch RSI (14) | 6.10 | Buy |
| CCI (20) | 58.27 | Neutral |
| Williams %R (14) | -26.60 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 9.32 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 73.40 | Neutral |
| TRIX (15) | 0.76 | Buy |
| Awesome (5,34) | 4.12 | Buy |
| Ultimate (7,14,28) | 60.02 | Neutral |
| Momentum (10) | 1.79 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 36.94 | Sell |
| ADX (14) | 30.64 | Buy |
| ATR (14) | 0.77 | Info |
The 30-day technical picture is bullish, with RSI14 at 70 indicating strong momentum.
Near-term technicals show the price trading above key moving averages, with SMA50 at $30.67 and SMA200 at $21.50, while the current price sits at $37.50. Support is noted at $27.40 and resistance at $37.50, framing a clear upside path.
The 30-day range runs from $32.36 to $43.46, reflecting active volatility, and annualized volatility sits around 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.35 | $36.61 | $47.61 | 0% | Neutral | |
| $38.99 | $48.20 | $62.63 | +32% | Bullish | |
| $48.96 | $61.91 | $83.01 | +69% | Bullish | |
| $59.33 | $76.43 | $105.03 | +109% | Bullish | |
| $71.61 | $93.77 | $131.58 | +156% | Bullish | |
| $78.72 | $104.63 | $149.51 | +186% | Bullish | |
| $84.75 | $114.21 | $165.89 | +212% | Bullish | |
| $96.66 | $131.95 | $194.53 | +260% | Bullish | |
| $107.06 | $147.96 | $221.14 | +304% | Bullish | |
| $134.28 | $187.75 | $284.21 | +413% | Bullish | |
| $193.98 | $285.83 | $456.57 | +681% | Bullish | |
| $407.43 | $655.89 | $1,133.84 | +16.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $14.35 | $36.61 | $43.00 | +0.00% |
| August 2026 | $30.78 | $36.16 | $43.49 | -1.24% |
| September 2026 | $31.48 | $37.20 | $45.16 | +2.87% |
| October 2026 | $31.60 | $37.52 | $45.90 | +0.86% |
| November 2026 | $31.20 | $37.20 | $45.82 | -0.83% |
| December 2026 | $32.10 | $38.42 | $47.61 | +3.28% |
Click any year to see its month-by-month ETON forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ETON price prediction for 2026 points to an average of $36.61 (low $14.35, high $47.61) — a potential gain of 0% on today's $36.61. A consolidation phase looks the most probable path here.
In 2027, ETON is projected to trade between $38.99 and $62.63, averaging $48.20 — a potential gain of +32% from today's $36.61. That is up +32% on the projected 2026 average. Momentum favours further upside here.
Eton Pharmaceuticals, Inc.'s 2028 outlook centres on $61.91, within a $48.96 to $83.01 range. That is up +28% on the projected 2027 average. That marks a +69% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ETON could reach as high as $105.03, with a base case around $76.43 and support toward $59.33 — roughly +109% from $36.61. Momentum favours further upside here.
Expect ETON to range from $71.61 to $131.58 through 2030. The $93.77 average target implies a +156% move from current prices. That is up +23% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ETON price prediction for 2031 points to an average of $104.63 (low $78.72, high $149.51) — a potential gain of +186% on today's $36.61. Momentum favours further upside here.
In 2032, ETON is projected to trade between $84.75 and $165.89, averaging $114.21 — a potential gain of +212% from today's $36.61. That is up +9% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Eton Pharmaceuticals, Inc.'s 2033 outlook centres on $131.95, within a $96.66 to $194.53 range. That is up +16% on the projected 2032 average. That marks a +260% change versus current levels. Momentum favours further upside here.
By 2034, ETON could reach as high as $221.14, with a base case around $147.96 and support toward $107.06 — roughly +304% from $36.61. Buyers look set to stay in control over this stretch.
Expect ETON to range from $134.28 to $284.21 through 2035. The $187.75 average target implies a +413% move from current prices. That is up +27% on the projected 2034 average. Momentum favours further upside here.
The ETON price prediction for 2040 points to an average of $285.83 (low $193.98, high $456.57) — a potential gain of +681% on today's $36.61. Buyers look set to stay in control over this stretch.
In 2050, ETON is projected to trade between $407.43 and $1,133.84, averaging $655.89 — a potential gain of +16.9x from today's $36.61. That is up +129% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ETON today (≈ 27.314941 ETON) could be worth
$17,915.53
+$16,915.53 (+1692%) by 2050 · US Dollar
Based on the average projected ETON price of $655.89 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ETONwould be worth at today's price.
$1,000 invested in ETON on Jul 10, 2025 (≈ 64.26735 ETON) would be worth
$2,352.83
+$1,352.83 (+135.3%) today · 2.35× · US Dollar
Based on a ETON entry price of $15.56 vs. today's $36.61.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $37.5 | $976.27 | -2.4% |
| 1 month ago | $30.95 | $1,182.88 | +18.3% |
| 3 months ago | $26.36 | $1,388.85 | +38.9% |
| 6 months ago | $15.47 | $2,366.52 | +136.7% |
| 1 year ago | $15.56 | $2,352.83 | +135.3% |
| All time (5.0y) ago | $5.62 | $6,514.24 | +551.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ETON forecast.
Our base-case forecast reaches $73.00 around 2029.
Implied market cap at $73.00: $2B
The multi-year forecast charts a clear bullish path. The 2026 average is $37.50, rising through the years to 2030 average of $94.45 (max $132.40) with an ROI of 151.8% and bullish sentiment. The subsequent years show continuing upside, with 2027 average $49.21 (max $63.95; ROI 31.2%), 2028 average $63.12 (max $84.60; ROI 68.3%), and 2029 average $78.22 (max $107.42; ROI 108.6%).
By 2030 the average reaches $94.45 (max $132.40) with a bullish stance and ROI of 151.8%, followed by 2031 average $105.42 (max $150.47; ROI 181.1%), 2032 average $115.41 (max $167.43; ROI 207.8%), 2033 average $131.64 (max $193.80; ROI 251%), and 2034 average $149.06 (max $222.46; ROI 297.5%). The trajectory continues to 2040 with an average of $283.51 (max $451.97; ROI 656) and culminates in 2050 with an average of $652.80 (max $1,125.67; ROI 1640.8%), all bearing bullish sentiment.
These figures are forecasts and not guarantees; actual results can differ. The year-by-year progression demonstrates substantial upside potential if the projected path holds.
Tap a question to reveal the answer.
Average: $94.45, Min: $72.18, Max: $132.40; ROI: 151.8%; sentiment: BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages and ROI (e.g., 2027 avg $49.21; ROI 31.2%; 2028 avg $63.12; ROI 68.3%; 2029 avg $78.22; ROI 108.6%; 2030 avg $94.45; ROI 151.8%). These are estimates and not guarantees.
Yes. The max forecast for 2034 is $222.46. The max forecasts later rise to $451.97 by 2040 and $1,125.67 by 2050.
Current price: $37.50; Market cap: $1.03B.
Sentiment is BULLISH with RSI 70.0, SMA50 is $30.67, SMA200 is $21.50. Support is $27.40 and resistance is $37.50. The 30-day range is $32.36–$43.46, with annualized volatility around 40%.
Eton Pharmaceuticals, Inc. Community Discussion
0Share your Eton Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.